Live Analyst Rating Changes 1941 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Gregory Renza
TRU
Gregory Renza
Wall Street Analyst
★☆☆☆☆
#2565
on 13Foresight · ranked by our own returns
34%
Success Rate
+3.3%
Average Return
17 of 50 calls profitable · -372.8% vs benchmark
📈 Across the calls we could measure, roughly 34% of Gregory Renza's ratings turned a profit when each position was held for 1 year — averaging +3.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

157 Buy 14 Hold 0 Sell
Gregory's Stock Coverage 40 ratings · 2026-06-23
Company Date Position Consensus Price Target 1-Yr Return
ABVX
Abivax SA Sponsored ADR
Jun 22, 2026 BUY Strong Buy
+18.1% avg upside
15 analysts
$135.00
32.72% Upside
·
ZYME
Zymeworks
Jun 18, 2026 BUY Strong Buy
+39.7% avg upside
25 analysts
+0.0%
JAZZ
Jazz Pharmaceuticals
Jun 18, 2026 BUY Strong Buy
-2.2% avg upside
35 analysts
+0.0%
GILD
Gilead Sciences
Jun 16, 2026 BUY Strong Buy
-5.3% avg upside
66 analysts
-2.7%
AGIO
Agios Pharma
Jun 15, 2026 BUY Strong Buy
+69.5% avg upside
29 analysts
$36.00
2.52% Upside
·
GMAB
Genmab
Jun 12, 2026 BUY Strong Buy
+37.2% avg upside
26 analysts
·
NUVB
Nuvation Bio
Jun 10, 2026 BUY Strong Buy
+127.0% avg upside
15 analysts
+25.8%
NUVL
Nuvalent
Jun 10, 2026 HOLD Buy
-0.2% avg upside
21 analysts
$124.00
0.55% Upside
+0.0%
NRIX
Nurix Therapeutics
Jun 09, 2026 BUY Strong Buy
+66.8% avg upside
26 analysts
$32.00
71.66% Upside
·
IDYA
IDEAYA Biosciences
Jun 02, 2026 BUY Strong Buy
+44.2% avg upside
29 analysts
+24.3%
FULC
Fulcrum Therapeutics
Jun 02, 2026 HOLD Hold
+134.6% avg upside
13 analysts
$4.00
6.04% Upside
·
ONC
BeOne Medicines
Jun 02, 2026 BUY Strong Buy
+27.8% avg upside
28 analysts
-1.7%
RVMD
Revolution Medicines
Jun 01, 2026 BUY Strong Buy
-13.2% avg upside
32 analysts
-0.4%
MNKD
MannKind
Jun 01, 2026 BUY Buy
+80.1% avg upside
22 analysts
·
VKTX
Viking Therapeutics
May 27, 2026 BUY Strong Buy
+129.3% avg upside
30 analysts
$83.00
156.42% Upside
-6.3%
CGON
CG Oncology, Inc.
May 27, 2026 BUY Strong Buy
+33.6% avg upside
17 analysts
+9.0%
REGN
Regeneron
May 18, 2026 BUY Strong Buy
+26.8% avg upside
57 analysts
$778.00
26.99% Upside
-2.6%
CATX
Perspective Therapeutics
May 12, 2026 BUY Strong Buy
+270.9% avg upside
22 analysts
-22.3%
XNCR
Xencor
May 07, 2026 BUY Strong Buy
+144.9% avg upside
27 analysts
$29.00
106.93% Upside
-8.5%
VRDN
Viridian Therapeutics
May 06, 2026 BUY Strong Buy
+93.9% avg upside
32 analysts
$35.00
98.54% Upside
-8.2%
WAY
Waystar Holding Corp.
May 04, 2026 BUY Strong Buy
+113.7% avg upside
29 analysts
$38.00
119.54% Upside
-11.8%
BCYC
Bicycle Therapeutics
May 01, 2026 HOLD Strong Buy
+507.9% avg upside
20 analysts
$7.00
75.88% Upside
-9.2%
AMGN
Amgen
May 01, 2026 HOLD Buy
-12.8% avg upside
57 analysts
$327.00
5.20% Downside
+6.0%
AAPG
Ascentage Pharma Group International Unsponsored ADR
Apr 24, 2026 BUY Strong Buy
+155.8% avg upside
10 analysts
$22.34
30.36% Upside
-28.1%
ACAD
ACADIA Pharmaceuticals
May 19, 2025 BUY Strong Buy
+63.1% avg upside
42 analysts
$26.00
17.60% Upside
-6.9%
ADCT
ADC Therapeutics
May 14, 2025 BUY Buy
+451.8% avg upside
12 analysts
$8.00
634.00% Upside
+85.6%
EXEL
Exelixis
May 13, 2025 BUY Strong Buy
-20.5% avg upside
33 analysts
$40.00
22.09% Downside
+38.8%
VRCA
Verrica Pharmaceuticals
May 13, 2025 HOLD Strong Buy
+223.7% avg upside
8 analysts
$20.00
254.71% Upside
+34.0%
VSTM
Verastem
May 13, 2025 BUY Strong Buy
+251.7% avg upside
23 analysts
$16.00
276.54% Upside
-36.7%
INO
Inovio Pharmaceuticals
May 13, 2025 HOLD Strong Buy
+808.6% avg upside
19 analysts
$5.00
350.47% Upside
-30.2%
JSPR
Jasper Therapeutics
May 12, 2025 BUY Strong Buy
+5846.6% avg upside
17 analysts
$46.00
9072.54% Upside
-80.7%
PCRX
Pacira Pharmaceuticals
May 08, 2025 HOLD Buy
+72.0% avg upside
21 analysts
$26.00
14.43% Upside
-7.1%
ATYR
aTyr Pharma
May 07, 2025 BUY Buy
+1956.5% avg upside
17 analysts
$16.00
3302.71% Upside
-70.9%
CRMD
Cormedix
May 06, 2025 BUY Strong Buy
+70.7% avg upside
13 analysts
$13.00
47.33% Upside
-27.9%
SPRB
Spruce Biosciences
May 06, 2025 HOLD Strong Buy
+84.9% avg upside
14 analysts
$37.50
31.43% Downside
-85.5%
TSE:APS
Aptose Biosciences
Nov 10, 2023 BUY Strong Buy
+4229.1% avg upside
10 analysts
$25.50
1103.02% Upside
·
AVTX
Avalo Therapeutics
Jun 26, 2023 HOLD Strong Buy
+229.5% avg upside
19 analysts
$180.00
953.96% Upside
-89.1%
APRE
Aprea Therapeutics
Mar 16, 2022 HOLD Buy
+2876.6% avg upside
7 analysts
$80.00
9980.60% Upside
-87.1%
ITRMF
Iterum Therapeutics
Nov 12, 2021 HOLD Buy
+18603.6% avg upside
5 analysts
$15.00
35957.72% Upside
·
BIIB
Biogen
Sep 08, 2015 BUY Buy
+23.7% avg upside
51 analysts
$348.00
74.26% Upside
-0.3%
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Gregory Renza — Frequently Asked Questions
How accurate are Gregory Renza's stock ratings?
Based on the calls 13Foresight could measure, about 34% of Gregory's ratings were profitable over a one-year hold, with an average return of +3.3% per rating, or -372.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Gregory ranked on 13Foresight?
Gregory Renza is currently ranked #2565 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Gregory cover?
Gregory most recently has ratings on ABVX, ZYME, JAZZ, GILD, AGIO, GMAB, NUVB, NUVL, NRIX, IDYA, FULC, ONC and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.